Apellis Stock Buy Hold or Sell Recommendation

APLS
 Stock
  

USD 50.10  0.54  1.07%   

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Apellis Pharmaceuticals is 'Hold'. Macroaxis provides Apellis Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding APLS positions. The advice algorithm takes into account all of Apellis Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
  
The advice is provided from Apellis Pharmaceuticals' buy-and-hold perspective. Please continue to Apellis Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Apellis and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Apellis Pharmaceuticals.

Execute Apellis Pharmaceuticals Buy or Sell Advice

The Apellis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Apellis Pharmaceuticals. Macroaxis does not own or have any residual interests in Apellis Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Apellis Pharmaceuticals' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Apellis PharmaceuticalsBuy Apellis Pharmaceuticals
Hold

Volatility

Details

Hype Condition

Details

Current Valuation

Details

Odds of Distress

Details

Economic Sensitivity

Details

Analyst Consensus

Details

Financial Strenth (F Score)

Details

Financial Leverage

Inapplicable
Details

Reporting Quality (M-Score)

Details
For the selected time horizon Apellis Pharmaceuticals has a Risk Adjusted Performance of (0.035388), Jensen Alpha of (0.16), Total Risk Alpha of (0.23) and Treynor Ratio of (0.31)
Our investment recommendation tool can be used to complement Apellis Pharmaceuticals trade advice provided by experts. It analyzes the company's potential to grow against your specific risk preferences and investment horizon. To make sure Apellis Pharmaceuticals is not overpriced, please confirm all Apellis Pharmaceuticals fundamentals, including its cash per share, beta, and the relationship between the revenue and cash flow from operations . Given that Apellis Pharmaceuticals has a price to earning of (6.94) X, we suggest you to validate Apellis Pharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Apellis Pharmaceuticals Trading Alerts and Improvement Suggestions

Apellis Pharmaceuticals generated a negative expected return over the last 90 days
Apellis Pharmaceuticals has high historical volatility and very poor performance
Apellis Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 96.64 M. Net Loss for the year was (638.42 M) with loss before overhead, payroll, taxes, and interest of (253.92 M).
Apellis Pharmaceuticals currently holds about 852.8 M in cash with (499.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76.
Apellis Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 89.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: GSK to slash about 150 consumer commercial jobs in India - FiercePharma

Apellis Pharmaceuticals current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Apellis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Apellis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price78.24
Target Median Price80.00
Target High Price123.00
Recommendation Mean1.80
Number Of Analyst Opinions17
Target Low Price40.00
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Apellis Pharmaceuticals Returns Distribution Density

The distribution of Apellis Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Apellis Pharmaceuticals' future price movements. The chart of the probability distribution of Apellis Pharmaceuticals stock daily returns describes the distribution of returns around its average expected value. We use Apellis Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Apellis Pharmaceuticals returns is essential to provide solid investment advice for Apellis Pharmaceuticals.
Mean Return-0.14Value At Risk-6.62
Potential Upside5.07Standard Deviation4.57
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Apellis Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Apellis Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Apellis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Apellis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares10.4 K471 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares11.6 K591 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares13.7 K646 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares7.3 K241 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares7.3 K462 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares7.2 K310 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares8.1 K465 K
Note, although Apellis Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Apellis Pharmaceuticals Cash Flow Accounts

201720182019202020212022 (projected)
Net Cash Flow or Change in Cash and Cash Equivalents150.78 M624 K175.72 M215.06 M74.71 M91.27 M
Net Cash Flow from Financing197.38 M131.9 M388.54 M692.18 M392.24 M318.22 M
Net Cash Flow from Operations(46.6 M)(131.24 M)(211.14 M)(160.49 M)(563.13 M)(577.95 M)
Share Based Compensation5.42 M7.73 M21.14 M45.38 M70.67 M76.25 M

Apellis Pharmaceuticals Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Apellis Pharmaceuticals or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Apellis Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Apellis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
-0.16
β
Beta against DOW0.47
σ
Overall volatility
4.58
Ir
Information ratio -0.04

Apellis Pharmaceuticals Volatility Alert

Apellis Pharmaceuticals exhibits very low volatility with skewness of 0.04 and kurtosis of 4.02. However, we advise investors to further study Apellis Pharmaceuticals technical indicators to ensure that all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Apellis Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Apellis Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Apellis Pharmaceuticals Fundamentals Vs Peers

Comparing Apellis Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Apellis Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Apellis Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Apellis Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Apellis Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Apellis Pharmaceuticals to competition
FundamentalsApellis PharmaceuticalsPeer Average
Return On Equity(661.83) %(0.31) %
Return On Asset(36.35) %(0.14) %
Operating Margin(512.22) %(5.51) %
Current Valuation5.87 B16.62 B
Shares Outstanding97.36 M571.82 M
Shares Owned by Insiders15.21 %10.09 %
Shares Owned by Institutions89.03 %39.21 %
Number of Shares Shorted8.78 M4.71 M
Price to Earning(6.94) X28.72 X
Price to Book79.38 X9.51 X
Price to Sales51.34 X11.42 X
Revenue96.64 M9.43 B
Gross Profit(253.92 M)27.38 B
EBITDA(493.6 M)3.9 B
Net Income(638.42 M)570.98 M
Cash and Equivalents852.8 M2.7 B
Cash per Share7.76 X5.01 X
Total Debt211.3 M5.32 B
Debt to Equity0.63 %48.70 %
Current Ratio7.57 X2.16 X
Book Value Per Share0.64 X1.93 K
Cash Flow from Operations(499.71 M)971.22 M
Short Ratio6.10 X4.00 X
Earnings Per Share(4.70) X3.12 X
Price to Earnings To Growth(0.30) X4.89 X
Number of Employees47618.84 K
Beta1.36-0.15
Market Capitalization4.96 B19.03 B
Total Asset115.95 M29.47 B
Retained Earnings(596.77 M)9.33 B
Working Capital110.69 M1.48 B
Current Asset115.82 M9.34 B
Current Liabilities5.13 M7.9 B
   Exercise or conversion by Pascal Deschatelets of 18500 shares of Apellis Pharmaceuticals subject to Rule 16b-3 [view details]

Apellis Pharmaceuticals Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Apellis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Apellis Pharmaceuticals Buy or Sell Advice

When is the right time to buy or sell Apellis Pharmaceuticals? Buying financial instruments such as Apellis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2010 2021 2022 (projected)
Receivables10.1 M9.09 M9.04 M
Inventories16.29 M14.66 M14.57 M

Use Investing Ideas to Build Portfolios

In addition to having Apellis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Recreation Thematic Idea Now

Recreation
Recreation Theme
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 28 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
View All  Next Launch
Please continue to Apellis Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for analysis

When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
2.9
Return On Assets
(0.46) 
Return On Equity
(5.07) 
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.